Clinical Trial Update: Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.

View source ↗

Summary

A post-marketing surveillance study in Japan evaluated the status and factors for developing peripheral neuropathy in breast cancer patients treated with eribul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Halaven (eribulin mesylate) (eribulin mesylate)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Breast Cancer, HER2-negative Breast Cancer | Status: COMPLETED